- From
- A$9.80/mo · ex-GST · billed in USD ($7 annual)
The gate: Five stars need 21+ and Australian Fit of at least 4/5.
Skip to the verdictArchived edition: our verdict as at 26 Jun 2026. Kept unchanged as the record of what we said then. Read the current edition: Elicit Review Australia 2026: The Serious Researcher's AI Literature Tool · Why we keep every edition
Verdict (TL;DR): Elicit is built for people who need to conduct systematic literature reviews at scale — pharmaceutical researchers, clinical academics, PhD candidates doing evidence synthesis. Its free tier is functional for casual exploration, but the tool's real power sits behind a pay wall that most Australians won't need to unlock. If you need to screen thousands of papers, extract structured data across dozens of variables, and produce PRISMA-grade review reports, Elicit is exceptional. If you want to quickly check what the science says on a question, Consensus or Perplexity will do that for less money. Also note: like all AI research tools, Elicit can misrepresent study findings. It is not a substitute for expert clinical, legal, or professional judgement.
Score: 15/25 — ⭐⭐⭐ Goodood
Last reviewed: 26 June 2026 by Adam.
What Elicit is
Elicit is an AI-powered research assistant built specifically for scientific literature. It began as a research project inside Ought Inc — a nonprofit research foundation — in 2021 and was spun out as an independent public benefit corporation in 2023. It is headquartered in the United States.
The tool is trusted by over 5 million researchers and is used by pharmaceutical companies, academic institutions, medtech firms, and policy bodies. Its headline claim: that it has achieved 95% search recall, 97% abstract screening accuracy, and 99% full-text screening accuracy across nearly 1,000 Cochrane systematic reviews (published May 2026).
Its database covers 138 million academic papers and 545,000 clinical trials. You can search, summarise, extract data from papers into tables, generate research reports, set alerts for new publications, and — at higher tiers — run full systematic review workflows to PRISMA 2020 standards.
Important caveat: Elicit uses AI to read, extract, and summarise research. AI models can miss context, misread statistical findings, or generate plausible-sounding but incorrect summaries. The company has published its own accuracy benchmarks, which are strong, but errors occur. Always verify critical claims against the original papers. For clinical, medical, or high-stakes professional decisions, consult a qualified expert. Elicit does not replace a clinician, lawyer, or professional adviser.
What it costs in Australia
All prices are in USD. AUD conversions at approximately 1.40 are estimates only. GST treatment for Australian subscribers is not disclosed on the pricing page — check your invoice.
| Plan | USD/month (annual) | AUD/month approx (annual) | AUD/year approx | Key limits |
|---|---|---|---|---|
| Basic | $0 | $0 | $0 | 2 Automated Reports/month, 2 table columns, limited Research Agent access |
| Plus | $7/month annual | ~A$9.80 | ~A$118 | 4 Reports/month, 5 table columns, clinical trial search, export to CSV/RIS/PDF |
| Pro | $29/month annual | ~A$40.60 | ~A$487 | 144 Reports or Systematic Reviews/year, 20 columns, 135 data sources, API access, paper alerts |
| Scale | $49/month annual | ~A$68.60 | ~A$823 | 240 Reports/year, 200 data sources, 30 columns, team collaboration, figure extraction |
| Enterprise | Custom | — | — | 40,000-paper screening, 40 columns, PRISMA-grade, SSO, dedicated success team |
Monthly billing is also available (Basic: free; Pro: $49/month; Scale: $169/month).
Source: elicit.com/pricing (verified 26 June 2026). Prices in USD; AUD conversion at ~1.40 is an estimate. Wayback: [snapshot queued]
How it works in practice
You start with a research question — typed in plain English. Elicit's semantic search means you do not need Boolean operators or exact keyword matches. It searches across 138 million papers and returns the most relevant results ranked by relevance.
From the results, you can:
- Build a table — select papers and add columns for specific data points (sample size, study design, outcome measure, country, etc.). Elicit extracts these automatically. This is where it becomes genuinely powerful for literature review work.
- Generate a Report — a structured research brief synthesising findings across multiple papers, with sentence-level citations. On Pro, a single report can draw from up to 135 data sources.
- Run a Systematic Review — on Pro and above, Elicit supports full systematic review workflows. You set inclusion/exclusion criteria, it screens thousands of papers, and you get a traceable, auditable process that meets PRISMA 2020 standards.
- Set Alerts — monitor 10 personalised research topics (Pro tier) for new publications and get notified automatically.
- Upload papers — add your own documents and extract custom data from them.
The Research Agent (launched late 2025) allows more autonomous, multi-step research exploration — give it a broad topic and it plans and executes a research landscape.
What it does well
Systematic reviews at scale. This is where Elicit has no real competitor for everyday users. Screening 5,000 papers to inclusion/exclusion criteria manually would take weeks. Elicit does it in hours. The accuracy benchmarks — validated across Cochrane reviews — are the strongest published by any AI research tool.
Transparency over chat. Every AI-generated claim is supported by sentence-level citations from the original source. You can trace every extraction back to the exact sentence in the paper. This is more rigorous than most AI tools.
Structured data extraction. The ability to extract specific variables from papers into a table — and then export to CSV, RIS, or PDF — is enormously useful for evidence synthesis. A researcher comparing 50 RCTs on a drug intervention can extract sample sizes, outcomes, and adverse event rates in a fraction of the time.
PRISMA 2020 compliance (Pro+). Elicit's Systematic Review workflow now meets PRISMA 2020 guidelines and produces reproducible, auditable outputs. This matters for clinical and policy research.
Improving rapidly. The platform has shipped substantial updates through 2025 and 2026, including clinical trial search, the Research Agent, figure extraction, and the PRISMA-compliant workflow. It is actively developed.
What it doesn't do well
It is expensive for occasional use. Pro at ~A$45/month annual (~A$539/year) is hard to justify unless you are conducting regular research. The free tier's two Reports per month disappears fast.
The free and Plus tiers are limited. Two Reports per month and two table columns is not much. If you are trying to do meaningful research work, you are on Pro — and the jump from Plus (~A$10.85/month) to Pro (~A$44.95/month) is steep.
It is not designed for quick answers. If you want to know "what does the science say about vitamin D deficiency?", Elicit is overkill. It is designed for researchers who need to process and synthesise literature at volume.
AI errors still occur. Despite strong accuracy benchmarks, Elicit can hallucinate extractions or misread statistical findings. The company publishes its benchmarks honestly, and they show the tool is genuinely accurate — but "95% recall" means 5% of relevant papers are missed. In clinical or systematic review work, that matters.
Data is in the United States. Elicit is a US company. Data is stored and processed in the US. Information may be transferred to third-party AI providers (under data processing agreements that prohibit training on your data). Australian organisations processing sensitive research data should consider APP 8 obligations. There is no Australian data residency option.
No AUD pricing, no local support. Prices are USD only. There is no Australian support team. For enterprise or institutional enquiries, you deal with a US-based sales team.
Australian fit
Elicit does not have Australian-specific features, AU pricing, or local data residency. It is a US product built for a global research market. Australian universities, hospitals, and pharmaceutical companies can and do use it, but they accept US data storage and USD billing.
The tool does not flag AU-specific considerations, does not have GST-inclusive pricing, and does not have a local support presence.
For the relatively small number of Australians who need it — academic researchers, pharmaceutical companies, research consultants conducting systematic reviews — these limitations are acceptable given there is no comparable Australian-built alternative. For everyone else, the AU fit issues compound the already high cost.
Australian Fit: 2/5. USD pricing only, US data residency, no local support, no AU-specific features or context.
Alternatives
- Consensus (reviewed in this issue) — Better for quick evidence lookups; much cheaper; the Consensus Meter is more useful for non-specialist questions. Less powerful for systematic review work.
- Perplexity AI — A strong general-purpose research AI. Not purpose-built for academic literature, but excellent for mixed-source research questions at a lower price point.
- Google's Gemini Notebook, formerly NotebookLM — Upload a defined set of papers and chat with them. Better for close reading of a known corpus; no search function across a broad database.
Bottom line
Elicit is the best AI tool available for systematic literature review work. If you are a researcher, a PhD candidate, a pharmaceutical company conducting evidence synthesis, or a policy team needing rigorous literature review at scale, it is worth every dollar of the Pro or Scale tier.
For the majority of Australians — including most business owners, professionals, and curious readers — it is more tool than they need. Start with Consensus or Perplexity and upgrade to Elicit only if you find yourself hitting their limits.
One non-negotiable reminder: Elicit can get things wrong. It is an AI tool reading research literature, not a licensed professional. Do not make clinical, medical, or high-stakes decisions on the basis of Elicit outputs alone. Verify against the original papers and consult a qualified expert.
Score
| Criterion | Score | Notes |
|---|---|---|
| Value for Money | 3/5 | Free tier is limited; Pro at ~A$539/year is justified for serious researchers but steep for casual users |
| Ease of Use | 3/5 | Clean interface but steep learning curve for systematic review workflows; not designed for quick lookups |
| Feature Depth | 4/5 | Best-in-class for systematic reviews; PRISMA 2020 support, 138M papers, figure extraction, full audit trails |
| Australian Fit | 2/5 | USD pricing, US data storage, no local support, no AU-specific features |
| Reliability & Support | 3/5 | Published accuracy benchmarks are strong; AI errors still occur; US-based support only; actively developed |
| Total | 15/25 | ⭐⭐⭐ Good |
Rating: ⭐⭐⭐ Good
Frequently asked questions
Is Elicit available in Australia?
Yes, Elicit is available to Australian users via web browser. It prices in USD, stores data in the United States, and has no Australian-specific support. Australian organisations processing sensitive research data should consider their obligations under APP 8 of the Australian Privacy Principles.
What does Elicit cost in Australian dollars?
The Basic tier is free. Plus costs approximately A$9.80/month on the annual plan (USD$7 × 1.40). Pro costs approximately A$40.60/month annual (USD$29 × 1.40), or about A$487/year. Scale costs approximately A$68.60/month annual. All prices are USD; AUD figures are estimates at a 1.40 exchange rate.
Can Elicit replace a professional researcher or clinician?
No. Elicit is an AI tool that can summarise and synthesise published research, but it can make errors, miss papers, and misrepresent findings. It does not replace the judgement of a qualified clinician, academic researcher, or other expert. For medical, clinical, or high-stakes decisions, always consult a qualified professional and verify AI outputs against original sources.
Sources
Primary: - Elicit pricing page: https://elicit.com/pricing (verified 26 June 2026) — contemporaneous snapshot still owed — Wayback 6 September 2026 - Elicit homepage and features: https://elicit.com/ (verified 26 June 2026) — Wayback: [snapshot queued] — Wayback 20 June 2026 - Elicit accuracy evaluation (May 2026): https://elicit.com/ — "Elicit hit 95% search recall, 97% abstract screening, 99% full-text screening" (verified 26 June 2026) — Wayback: [snapshot queued] — Wayback 20 June 2026 - Elicit privacy policy: https://elicit.com/operations/privacy (verified 26 June 2026) — contemporaneous snapshot still owed — Wayback 19 August 2026
Secondary: - TechCrunch: "Elicit is building a tool to automate scientific literature review" (September 2023) — company background - Deakin University Library Guide on Elicit: https://deakin.libguides.com/AI-Evaluations/Elicit — supporting context on data privacy — Wayback 3 September 2026 - USD to AUD conversion at approximately 1.40 (September 2026). GST treatment (confirm GST treatment at checkout).
The AI Directory Australia is an independent editorial publication. We don't accept payment for positive reviews. Read our Methodology and Affiliate Disclosure.